Feb 23 2013, 4:08am CST | by Luigi Lugmayr
Washington, Feb 23 — Breast cancer patients will now have an effective and less toxic therapeutic option.
On Friday, the Food and Drug Administration (FDA) approved the new treatment drug, Kadcyla (trastuzumab emtansine), also known as TDM-1, which combines Traztuzumab, also called Herceptin, with the powerful chemotherapy drug emtansine.
The drug therapy is developed by Roche-owned Genentech, which funded the study.
Results from clinical trials of the drug TDM-1, known as "Super Herceptin," showed that it was more effective and less toxic than the standard regimen for this type of tumour.
The medication kept patients free of disease for longer than the standard chemotherapy regimen.
HER-2 positive breast cancer patients have been found to be positive for carrying a protein that promotes the growth of cancer cells.
TDM-1 is taken directly to cells that have the HER2 protein on the membrane, such as the cancer cells, while sparing normal cells. This results in less toxicity from the chemotherapy drug, reports Science Daily.
"TDM-1 works like the original drug Herceptin by hunting down and interfering with the cancer cells," said Melody Cobleigh, director of the Comprehensive Breast Centre at Rush centre, Illinois and lead investigator of the TDM-1 clinical trials at Rush.
Luigi is the founding Chief Editor of I4U News and brings over 15 years experience in the technology field to the ever evolving and exciting world of gadgets. He started I4U News back in 2000 and evolved it into vibrant technology magazine.
Luigi can be contacted directly at email@example.com. Luigi posts regularly on LuigiMe.com about his experience running I4U.
blog comments powered by Disqus